COVID-19 rapid antigen test

Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

Thursday, July 22, 2021 - 2:24pm

Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.

Key Points: 
  • Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.
  • "We're excited to share our overall 264 test results from our Brazilian AcuVid Saliva / RT-PCR Test Clinical Study.
  • The additional 201 test results, on top of the initial 63, not only exceed FDA-EUA minimum requirements, but confirms the performance quality and ease-of-use of our AcuVid saliva test.
  • In fact, our complete AcuVid study achieved comparable, and in some cases, better performance results than other leading COVID-19 rapid antigen tests available on today's market," expressed Rob Fia, CEO of Therma Bright.

Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests

Wednesday, June 30, 2021 - 2:00pm

The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.

Key Points: 
  • The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.
  • The distribution partnership between Vivera, Areum Bio, and Access Bio will help make rapid testing more readily available as quickly as possible.
  • "This co-branded collaboration marks a new strategic alliance for Vivera," said Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals.
  • "This is a great opportunity for Areum Bio to partner with Vivera, a reputable pharmaceutical company, for the nationwide distribution of the CareStart COVID-19 Rapid Antigen Tests," said Dr. Jong Kim, President of Areum Bio.

LivFul and Global Access Diagnostics announce partnership for COVID-19 test kit distribution

Wednesday, June 9, 2021 - 11:14am

LIVERPOOL, England, June 9, 2021 /PRNewswire/ --LivFul and Global Access Diagnostics (GAD)today announced a new partnership to make a variety of diagnostic kits, starting with COVID-19 rapid antigen tests, available in Low to Middle Income Countries.

Key Points: 
  • LIVERPOOL, England, June 9, 2021 /PRNewswire/ --LivFul and Global Access Diagnostics (GAD)today announced a new partnership to make a variety of diagnostic kits, starting with COVID-19 rapid antigen tests, available in Low to Middle Income Countries.
  • This partnership will bring rapid antigen test kits to the market at an affordable price.
  • We are aligned in driving access to our COVID-19 antigen test for as many people as possible."
  • "LivFul was founded to expand health access with products that transform lives and business models that reach all people.